In the Phase III EMBRACA trial (NCT01945775) that followed, patients with germline BRCA1/2-mutated HER2- advanced breast cancer treated with 1 mg once daily talazoparib had significantly longer progression-free survival and clinically meaningful improvements in patient-reported outcomes compared with physician's choice of chemotherapy [20], leading to regulatory approvals for this indication in the US, EU, and multiple other countries [25,26]. Here, BRCA1 is linked to breast carcinoma.